Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Scientists have finally explained a decades-old mystery in inflammatory bowel disease — and the culprit is a rogue antibody. Researchers found that some IBD patients produce antibodies that block interleukin-10, a key protein that keeps inflammation in check, and that blood antibody patterns can flag IBD risk up to 10 years before diagnosis. Together, these breakthroughs could pave the way for earlier detection and more targeted treatments.
Two major breakthroughs are reshaping how we understand inflammatory bowel disease
Scientists from Oxford, Newcastle, and Cambridge have cracked a 30-year mystery in IBD research: some patients produce antibodies that block interleukin-10 (IL-10), a protein that normally keeps the immune system's inflammatory response in check. Published in the New England Journal of Medicine, the study of over 4,900 IBD patients also explains why a well-known genetic variant — HLA-DRB1*01:03 — dramatically raises the risk of severe IBD. Carriers of this gene are far more likely to develop these IL-10-blocking antibodies, finally connecting the genetic dots researchers have been chasing since the 1990s.
Meanwhile, a separate study presented at UEG Week 2026 found that distinct antibody patterns in the blood can distinguish future IBD patients from healthy individuals up to a decade before diagnosis — with AI models achieving strong predictive accuracy (AUC 0.90 for Crohn's, 0.84 for ulcerative colitis).
By the Numbers
Why it matters: These discoveries open the door to blood tests that could catch IBD years earlier and identify patients whose disease stems from a specific immune malfunction — enabling truly targeted therapies, fewer hospitalizations, and potentially significant healthcare savings.
